[177Lu]Lu-PSMA-617, targets the prostate specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCP II), which is shown to be overexpressed in 90–100% of prostate cancer cases [4]. Here, FOLH1 is linked to prostate carcinoma.